Iris BioTechnologies Launches Proprietary Informatics Database, BioWindows(TM)
2008-05-13 20:31:00 -
www.irisbiotech.com - The Investor Relations Group 212-825-3210 Investor Relations: Conrad F. Mir conrad@investorrelationsgroup.com or Christine Berni christine@investorrelationsgroup.com or Media Relations: Hayden Lynch hayden@investorrelationsgroup.com Iris BioTechnologies (OTCBB: IRSB, www.irisbiotech.com), a theranostics company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, has launched its proprietary database, BioWindows(TM).
A computer based survey program, BioWindows(TM) is designed for individuals to compile personalized in-depth profiles to help determine the most appropriate medical solution. Each individual confidentially enters personal information, including demographics, medical history, and lifestyle choices, into a database. This survey, in combination with a specific tissue biopsy, allows for medical professionals to accurately assess the most optimal form of treatment. The database facilitates comparisons with a central repository of gene profiles to assist doctors and scientists in using targeted diagnostic to personalize medical treatments.
"The launch of our informatics system, BioWindows(TM), is paving the way for Iris's debut in the public marketplace," says Simon Chin, founder, chairman, and chief executive officer of Iris BioTechnologies. "It signifies a critical step for Iris as it evidences our team's hard work and commitment to the company's mission and to the field of personalized medicine."
Iris BioTechnologies is dedicated to identifying gene expression patterns. By profiling genomic information using their patented Nano-BioChip(TM) and analyzing these patterns and important factors contained in the interactive BioWindows survey, Iris has designed a remarkably comprehensive personalized medicine platform.
"Our BioWindows(TM) platform, coupled with our proprietary Nano-BioChip(TM), will soon help to identify effective methods to optimize breast cancer treatment, reduce both disease risk and medical costs while ultimately improving the patient quality of life," Chin continues. "The information garnered by our database will not only help patients and their families, but those in generations to follow. There is currently a void in our medical system when it comes to targeted, individualized treatment, and we believe we have the solution."
For more information about BioWindows(TM), please visit: www.youtube.com/watch?v=TJoEmAzNB7c or our corporate website: www.irisbiotech.com
About Iris BioTechnologies
Iris BioTechnologies (www.irisbiotech.com), located in Santa Clara, CA, is a theranostics company, dedicated to creating a novel approach to monitor gene expression levels and mutations in order to identify the ideal treatment solution for patients. By categorizing individuals according to their genomic and personal profiles, Iris BioTechnologies accurately determines the optimal medical solution for each patient through a proprietary informatics program, BioWindows. Iris's ever expanding database, in addition to their developments of the Comprehensive Cancer Chip(TM), NeuroChip(TM), CardioChip(TM), and MetabolicChip(TM) adds to their extensive product pipeline. The company's first biochip, the BreastCancerChip, is expected to be available in the second half of 2008.
For further information, visit the company website at www.irisbiotech.com.
Forward-Looking Statements
The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
International Survey Program to Improve Personalized Medicine
